Annovis Bio Inc. Common Stock (ANVS)
Stock · NYSE · Health Care
$1.72as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$1.73
Industry
Biotechnology: Pharmaceutical Preparations
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and A…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- www.annovisbio.com/
Fundamentals
- 1-day range
- $1.71$1.83
- Market cap
- $59.59M
- P/E (trailing)
- —
- P/E (forward)
- -1.92
- EPS (trailing)
- $-1.70
- Dividend yield
- —
- Beta
- 1.17
- Avg. volume
- 813.0K
52-week range
$1.54$5.5
Forecasts
3 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$17
+888.4%
Median
$8
+365.1%
Low
$8
+365.1%
Annovis Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANVSAnnovis Bio Inc. Common Stock$1.72▼ 4.97%Market cap $59.59MP/E —$1.54$5.5
- XLOXilio Therapeutics Inc. Common Stock$9▼ 0.22%Market cap $59.51MP/E —$6.47$12.74
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.22▼ 1.61%Market cap $59.73MP/E —$1.02$1.88
- DOMHDominari Holdings Inc. Common Stock$2.39▼ 4.02%Market cap $58.34MP/E —$2.19$8.4
- CTORCitius Oncology Inc. Common Stock$0.776▼ 1.77%Market cap $58.15MP/E —$0.491$2.25
- BOLDBoundless Bio Inc. Common Stock$2.83▼ 1.05%Market cap $57.73MP/E —$0.9612$3.16
- DWTXDogwood Therapeutics Inc. Common Stock$2.6▲ 12.07%Market cap $57.51MP/E 1.84$1.28$9.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANVS Annovis Bio Inc. Common Stock | $59.59M | — | $1.72 | ▼ 4.97% | $1.54$5.5 |
| XLO Xilio Therapeutics Inc. Common Stock | $59.51M | — | $9 | ▼ 0.22% | $6.47$12.74 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $59.73M | — | $1.22 | ▼ 1.61% | $1.02$1.88 |
| DOMH Dominari Holdings Inc. Common Stock | $58.34M | — | $2.39 | ▼ 4.02% | $2.19$8.4 |
| CTOR Citius Oncology Inc. Common Stock | $58.15M | — | $0.776 | ▼ 1.77% | $0.491$2.25 |
| BOLD Boundless Bio Inc. Common Stock | $57.73M | — | $2.83 | ▼ 1.05% | $0.9612$3.16 |
| DWTX Dogwood Therapeutics Inc. Common Stock | $57.51M | 1.84 | $2.6 | ▲ 12.07% | $1.28$9.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7benzinga · 8/28/2026
- Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7Benzinga · 8/28/2026
- Annovis Bio Q2 EPS $(0.40) Beats $(0.45) EstimateBenzinga · 8/14/2026
Insider Activity
Insider Actions →Acquired
790.1K
Disposed
0
- Hoffman Michael B · May 20, 2026 · Buy54.9K @ $1.9
- Hoffman Michael B · May 20, 2026 · Buy18.8K @ $1.8
- Hoffman Michael B · May 20, 2026 · Buy2.6K @ $1.75
- Hoffman Michael B · April 2, 2026 · Buy713.8K @ $2.1
Institutional Ownership
March 31, 2026
- Total shares held
- 5.09M
- Total value held
- $11.09M
- Institutional holders
- 55
Top holders this quarter
- Unknown1.19M
- Unknown872.4K
- Unknown627.7K
- Unknown541.0K
- Unknown347.6K
- Unknown247.5K
- Unknown141.7K
- Unknown139.5K
- Unknown104.9K
- Unknown86.7K
See the full, filterable feed with live charts on the MarketWall dashboard.